Background-Although most treatment for non-small celi lung cancer is palliative, data on the adequacy of symptom control are scanty and there has been little discussion about the appropriate indices. Methods-Two hundred and eighty nine unselected patients presenting sequentially to six specialists were studied; 242 cases were confirmed histologically and all were managed as non-small cell lung cancer. At presentation and two monthly for one year or until death each of 12 symptoms was graded by a physician at a clinic interview on a four point scale as absent, mild, moderate, or severe. For each symptom a palliative index (median duration of controlmedian duration of survival) was calculated, where control was defined as an improvement in symptoms of any severity by one grade or more.
Results-Sixty four (22%) patients had surgery, 15 (5%/O) radical and 107 (37%/6) palliative radiotherapy, and 103 (36%) best supportive care. Analysis showed that most symptoms inexorably worsened with time. The palliation index for haemoptysis was 86%, chest pain 73%, cough 34%, and breathlessness 30%; for systemic symptoms it was 54%/o for anorexia and 47% for malaise. Palliation was poor in many patients after surgery. Breathlessness was a particular problem in the group having best supportive care. Conclusions-The frequency of most symptoms in non-small cell lung cancer increases inexorably with time until malaise and anorexia are almost universal. Haemoptysis and chest pain are better palliated than cough and breathlessness. Present treatments fail to give adequate palliation for many patients, and the emphasis in future therapeutic studies should be on the relief of the more severe symptoms. there is no evidence that most patients have their prognosis appreciably altered by medical treatment or that their prognosis has improved over the last 10 years.23 Consequently the role of non-surgical management in non-small cell lung cancer is to palliate symptoms. Apart from studies on radiotherapy regimens45 and a little work on terminal care,67 however, there have been no detailed assessments of the efficacy of symptom relief or of the pattern and development of symptoms after presentation. It is important to acquire such data because any consequent changes in the management of non-small cell lung cancer will have major practical and economic consequences. 8 As part of a multicentre prospective study in the management of non-small cell lung cancer in our region, we have examined the pattern of symptoms and palliation in nearly 300 unselected patients presenting to four physicians and two radiotherapists. (2) they had an abnormality on their chest radiograph at presentation that worsened during the period of observation; (3) they had a clinical course during observation that was compatible with progressive carcinoma or they died during the period of observation with evidence of an enlarging tumour or metastatic disease; (4) they did not have a serum neurone specific enolase value greater than 12 U/ml; (5) they had no evidence of a primary tumour elsewhere. The clinical course of these patients was indistinguishable from that of patients with histological confirmation.
Methods

STATISTICAL METHODS
Trends in symptoms with time As symptoms at presentation represent a cross section of times during the natural history of the disease, trends in the proportion of patients having a particular symptom, regardless of its severity, were related to death rather than presentation. Thus cohorts were identified according to how many months before death a patient presented. The trends were described for each of these cohorts to confirm that the changes were similar throughout; the data were then combined and the resulting trend was assumed to be representative of the experience of all patients irrespective of the time of presentation and therefore to be a true reflection of the actual changes.
Palliation of symptoms
The degree of palliation of symptoms was expressed in terms of a percentage palliation index:
median duration of control of a symptom x 100. median duration of follow up period
The duration of symptom control was defined as the period of time after onset during which a symptom's severity was reduced. The symptom follow up period was taken to extend from the point of the symptom's first occurrence either to death or to the end of the study. This method of measuring the palliation of symptoms was chosen as it took into account the variable duration of survival.
The improvement between different points on a symptom scale cannot be assumed to have the same impact and so the palliation index (PI) was calculated in two ways: (17) 4 (1) 38 (13) 7 (2) PI [1] : when all grades at presentation (severe, moderate, mild) improved by one grade or more; PI [2] : when severe or moderate symptoms were improved at least to mild and initially mild symptoms improved by one grade or remained unchanged. Patients for whom the symptom was recorded as absent throughout were excluded. The palliation index for performance status was expanded from PI [1] to include the maintenance of grade 0.
Results
PATIENTS
The original population consisted of 330 patients. Two hundred and forty two had tumours histologically confirmed as nonsmall cell lung cancer. Review of the 88 patients without histological confirmation showed that 11 had small cell lung cancer and 23 had non-cancerous lesions; data were insufficient in seven cases. The remaining 47 fulfilled the criteria given above in support of a diagnosis of primary non-small cell lung cancer and were included in the analysis. Thus the final population consisted of 289 patients (232 men), mean age 66 (SD 9 64) years. The distribution between centres was: physician 1-92 patients; physician 2-83; physician 3-47; physician 4-17; radiotherapist 1-35; radiotherapist 2-12.
Data on patients at presentation were complete. The numbers of patients potentially providing data at the subsequent follow up visits were: 2 months-260 (90%), 4 months-234 (81%), 6 months-214 (74%), and 12 months-165 (57%).
MANAGEMENT AND SURVIVAL
The initial management of these 289 patients was surgery in 64 patients (22%), radical radiotherapy in 15 (5%), immediate palliative radiotherapy in 107 (37%), and best supportive care in 103 (36%). The patients having best supportive care had no immediate anticancer treatment and only 12 had later palliative radiotherapy. Their mean age was 70 years and the distribution of their initial performance status ratings was not different from that of the group as a whole. The proportions of the group having best supportive care and of the whole group falling into the different WHO grades were: Grade 0-23% and 87/289 (30%); grade 1-37% and 36%; grade 2-29% and 28%; grade 3-8% and 5%; grade 4-3% and 2%.
The patients' survival at 12 months according to their initial management was:
surgery 33/64 (52%), radical radiotherapy 7/15 (47%), palliative radiotherapy 22/107 (21%), best supportive care 20/103 (19%).
The median survival was 6 (interquartile range 3-14) months overall, 6 (3-11) months after palliative radiotherapy, and 4 (1-8) months with best supportive care.
SYMPTOMS AT PRESENTATION (TABLE 1) As expected, the most common and severe symptoms were cough and breathlessness. Months before death These were experienced by three quarters of patients, and were moderate or severe in about half of these. Haemoptysis and chest pain were present in just over one third but severe symptoms were rare. Other localised symptoms were much less common. One hundred and thirty (45%) of the 289 patients presented with systemic symptoms of anorexia or malaise, which were moderate or severe in 57 (19%) and 49 (17%).
CHANGE OF SYMPTOMS WITH TIME (FIGURE) As the figure shows, most symptoms eventually became more common despite efforts at palliation. Although haemoptysis and cough showed less change, chest pain, breathlessness and in particular the systemic symptoms malaise and anorexia increased inexorably. This illustrates why the last two are such powerful negative prognostic factors in the disease.
PALLIATION OF SYMPTOMS (TABLE 2)
From the whole population of 289 the number of patients experiencing any grade of each symptom and the corresponding palliation indices are shown on the left hand side of table 2. Blanks indicate where the numbers are too small for analysis. For PI [1] , among the respiratory symptoms haemoptysis and Table 3 shows symptom palliation in each initial treatment group on the basis of PI [2] for all grades (left hand columns). PI [1] and PI [2] are the same where moderate or severe symptoms only are considered (right hand columns). Haemoptysis of any severity was well palliated whatever treatment was given. Surgery is considered curative treatment but it did not eliminate all the symptoms found at presentation. For example, chest pain, including both tumour related pain and post-thoracotomy pain, had a palliative index of only 63% in the surgically treated patients. The pattern of palliation after radiotherapy was broadly similar to that in the whole group. For the patients having best supportive care, however, the pattern was unexpected. Cough was surprisingly well controlled (PI 95%) but breathlessness responded poorly to treatment (PI 37%).
MEDICAL TREATMENT
Two hundred and twenty nine (79%) of all the patients were recorded as having had drugs for symptom relief at some stage. Corticosteroids were given to 69 (24%), new bronchodilators to 29 (10%), antitussives to 46 (16%), and analgesics to 103 (36%). The group having best supportive care did not receive proportionately more treatment of this type than the other patients.
Discussion
In this paper we have shown that for unselected patients with non-small cell lung cancer systemic and some respiratory symptoms become more common as time passes even though they receive appropriate conventional treatment. Palliation therefore is variable, with haemoptysis and chest pain well controlled but cough and breathlessness much less so.
Much effort and study has been applied to the measurement of the "quality of life" of patients undergoing treautent for cancer. [1] [2] [3] Complex questionnaires are available that have been validated by correlation with in depth psychometric interviews. We deliberately did not attempt to derive or use a global score for quality of life because we particularly wanted to concentrate on the success or otherwise of control of the physical symptoms for which patients with this disease are referred for treatment.
The clinical grading system we used has the merit of rapidity and simplicity. The only comparisons between clinic recall and the diary card system that we know of is a Medical Research Council (MRC) study. '4 This showed a good concordance between the two methods and supports the contention that the symptom gradings reported by our patients did represent what they were really experiencing.
COMPARISON WITH PREVIOUS STUDIES
Previous studies measuring palliation in nonsmall cell lung cancer have considered only patients referred particularly for radiotherapy4515 or surgery. '6 17 Primary chemotherapy is rarely used in the United Kingdom for non-small cell lung cancer, and no studies have focused particularly on palliation after it. Our study population included patients treated by radiotherapy and surgery and also the third of patients who were treated by physicians and not referred. This group has not previously been studied.
Nou et al'6 showed that patients undergoing surgery and subsequently relapsing have substantial symptoms and our study reinforces this. Over 40% of our surgically treated patients died within the first year and the palliation indices in this group were not better than in the other groups (table 3) .
The format of our study allows a comparison of symptom palliation in our patients and in those of the recent radiotherapy dosage study by the MRC working party, which used a similar index.5 If mild, moderate and severe breathlessness on our scale are equated with 3-5 on the MRC scale the comparisons are as follows:
For the PI [1] in our study: cough 18%, haemoptysis 98%, breathlessness 41%, chest pain 72%; for the MRC study: cough 50%, haemoptysis 80%, breathlessness 50% and chest pain 57%.
Comparison with the few other studies is more difficult. Slawson 
SEVERITY OF SYMPTOMS AND THEIR IMPACT
The MRC study5 gave equal weight to the relief of a mild symptom (which becomes absent) and the improvement from severe to absent. There are reasons for believing that a more appropriate index in the setting of nonsmall cell lung cancer may be to regard palliation as adequate if severe or moderate symptoms are reduced to mild or absent and mild symptoms remain and do not worsen (PI [2] ). This is because nearly all patients with non-small cell lung cancer are current smokers or ex-smokers with a high background incidence of cough, sputum, breathlessness, and variable chest tightness due to diffuse airway disease, which pre-exists and persists alongside the local effects of their tumour. The focus of palliation then becomes the patient who presents with moderate or severe symptoms and in whom the target of palliation should be to make symptoms mild or absent. This suggestion seems clinically appropriate but needs validation for nonsmall cell lung cancer by correlating the reported severity of each symptom with an assessment of its impact and the concern a patient feels about it.
SYMPTOMS
Haemoptysis is palliated whatever treatment policy for non-small cell lung cancer is adopted (table 3) . Chest pain deriving from lung cancer has not been analysed in detail in any prospective study. We have shown that it persists after surgery, when it presumably relates to the thoracotomy. We believe that this symptom merits a further, more detailed analysis to establish which types of pain respond to direct antitumour treatment. Cough and breathlessness are the major respiratory symptoms of lung cancer and are less well palliated. Coexistent diffuse airway disease, however, is likely to be a component of the symptom pattern in many patients and its severity and response to therapy has not, so far as we are aware, been studied prospectively in any series.
Corticosteroids are the only widely used treatment to ameliorate the systemic symptoms of malaise and anorexia in non-small cell lung cancer. Anecdotally they seem to have a transient effect in milder cases. As the analysis of symptom pattern shows (figure), systemic symptoms are likely to dominate activity scores and quality of life assessments later in the disease in all patients.
Palliation of the less common subsidiary symptoms in non-small cell lung cancer is fairly good, to judge by palliation indices of 60% or more (table 2). The number of patients presenting with moderate or severe subsidiary symptoms (less than 7%) is too small for comparisons between treatment modalities to be made.
